Holen Sie sich die Stockscreener-App
7.405
2.89%
-0.195
Schlusskurs vom Vortag:
$7.60
Offen:
$7.6
24-Stunden-Volumen:
25,626
Relative Volume:
0.09
Marktkapitalisierung:
$139.48M
Einnahmen:
$107.35M
Nettoeinkommen (Verlust:
$6.84M
KGV:
20.97
EPS:
0.3532
Netto-Cashflow:
$14.64M
1W Leistung:
-8.21%
1M Leistung:
+4.24%
6M Leistung:
+7.89%
1J Leistung:
-58.52%
1-Tages-Spanne:
$7.32
$7.60
1-Wochen-Bereich:
$7.32
$8.335
52-Wochen-Spanne:
$4.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Firmenname
Optimizerx Corp
Sektor
Branche
Telefon
248-651-6558
Adresse
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, BTSG, TEM, TXG, HQY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
7.405 | 143.15M | 107.35M | 6.84M | 14.64M | 0.3532 |
VEEV
Veeva Systems Inc
|
262.74 | 42.88B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.90 | 12.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
63.38 | 11.67B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
66.88 | 8.55B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
93.65 | 7.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-07-25 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-04-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-02-02 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-11-01 | Eingeleitet | Stifel | Buy |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-18 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-01-03 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Optimizerx Corp Aktie (OPRX) Neueste Nachrichten
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference - marketscreener.com
A 10th annual growth conference is set for New York, with OptimizeRx taking part. - Stock Titan
Optimizerx Stock Price Forecast. Should You Buy OPRX? - StockInvest.us
OPTIMIZERx Corp (NASDAQ: OPRX) Share Price, OPRX Stock News, OPRX Share Price & Updates - kalkine.ca
OptimizeRx (OPRX) insider stock withheld for taxes - Stock Titan
OptimizeRx appoints Troy Sarich as company advisor By Investing.com - Investing.com Canada
OptimizeRx appoints Troy Sarich as company advisor - Investing.com
OptimizeRx Appoints Former Johnson & Johnson Executive Troy Sarich as Company Advisor - Quiver Quantitative
Johnson & Johnson’s former data chief joins OptimizeRx to guide AI tools - Stock Titan
OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
OptimizeRx (NASDAQ: OPRX) COO keeps 25,187 shares after RSU tax withholding - Stock Titan
OptimizeRx (NASDAQ: OPRX) reports new insider share transaction - Stock Titan
OPRX | OptimizeRx Corporation Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript - AOL.com
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
OptimizeRx (OPRX) Slips to $8.72 as Shares Consolidate Near Range MidpointInverse ETF Flow - vinanet.vn
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
Conferencia de resultados del segundo trimestre fiscal de 2026 de OptimizeRx (OPRX): Reitera previsiones mientras los ingresos caen un 30% - TradingKey
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - marketbeat.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Nigeria
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Earnings Call zu Q2 des Geschäftsjahres 2026: Prognose bestätigt, während der Umsatz um 30 % sinkt - TradingKey
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
Stifel cuts OptimizeRx stock price target on revenue headwinds By Investing.com - Investing.com Australia
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - The Manila Times
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
OptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M - scanx.trade
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO - Investing.com
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO By Investing.com - Investing.com India
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook - Stock Titan
OptimizeRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027 - Stock Titan
OptimizeRx Refinances Debt With $35M Facility, Pays Down $8.3M - Stock Titan
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside - finance.biggo.com
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside - Yahoo Finance
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OPRX News | OPTIMIZERX CORP (NASDAQ:OPRX) - ChartMill
Finanzdaten der Optimizerx Corp-Aktie (OPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Optimizerx Corp-Aktie (OPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stelmakh Edward | Chief Finance & Strat Officer |
Dec 19 '25 |
Sale |
13.51 |
1,388 |
18,752 |
126,830 |
| Silvestro Stephen L | Chief Executive Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
6,546 |
0 |
195,462 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
3,928 |
0 |
94,526 |
| Besch Doug | Chief Product & Tech Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
1,964 |
0 |
71,536 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
92,550 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
190,536 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Sale |
18.75 |
1,620 |
30,375 |
188,916 |
| Stelmakh Edward | Chief Finance & Strat Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
16,623 |
0 |
127,387 |
| Besch Doug | Chief Product & Tech Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
3,325 |
0 |
70,555 |
0.02%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):